Bioverativ

66 articles about Bioverativ

• ALPROLIX Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study

  12/11/2017

  The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when compared with conventional factor IX and a glycoPEGylated factor IX analog.

• U.S. Label Update for Bioverativ's ALPROLIX Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children With Hemophilia B

  11/27/2017

  These updates are based on interim data from the Phase 3 B-YOND open-label extension trial and final data from the Phase 3 Kids B-LONG pediatric study.

• Bioverativ Release: Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment With ELOCTATE

  10/31/2017

  Interim data show participants enrolled in the ASPIRE extension study demonstrated continuous improvement in joint health over a nearly three-year period with prophylactic dosing of ELOCTATE.

• Bioverativ Reports Third Quarter 2017 Performance

  10/27/2017

  Bioverativ Inc. today reported financial results for the third quarter of 2017.

• Bioverativ To Report Third Quarter 2017 Financial Results On October 26, 2017

  9/28/2017

• Tiny Bicycle Therapeutics Wrangles a $424 Million R&D Pact With Biogen Spinoff Bioverativ

  9/7/2017

• Bioverativ And Invicro Form Novel, Advanced Imaging Collaboration Focused On Improving Management Of Joint Health In People With Hemophilia

  8/24/2017

• Bioverativ Reports Second Quarter 2017 Performance

  8/3/2017

• Why Biogen Spinoff Bioverativ's Anemia Drug Could Be A Blockbuster

  7/11/2017

• Bioverativ To Report Second Quarter 2017 Financial Results On August 2, 2017

  7/7/2017

• New Data To Be Presented At Isth Underscore Bioverativ’s Commitment To Advance Hemophilia Care

  7/6/2017

• Bioverativ And Swedish Orphan Biovitrum Highlight Commitment To Improving Care For People With Hemophilia At ISTH 2017 Congress

  7/6/2017

• Bioverativ Completes Acquisition Of True North

  6/29/2017

• Bioverativ Announces FDA Acceptance Of Investigational New Drug Application For BIVV001 To Treat Hemophilia A

  6/12/2017

• Biogen Spinoff Bioverativ Takes Out Bay Area's True North in $825 Million Deal

  5/24/2017

• Bioverativ Appoints Geno J. Germano To Company’s Board Of Directors

  5/16/2017

• Bioverativ Reports First Quarter 2017 Results

  5/4/2017

• Bioverativ Appoints Tim Harris Executive Vice President, Research And Development

  4/10/2017

• Bioverativ To Report First Quarter 2017 Financial Results On May 3, 2017

  4/6/2017

• How Biogen Spinoff Bioverativ and Its Hemophilia Med Could Make This Biotech Bleed

  3/23/2017